Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus PENTACEF.
ANSPOR vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic